Viridian reports $645.7M cash, $237.7M net loss; VRDN-001 Phase 3 readouts mid-2024

Viridian Therapeutics, Inc.\DE

2023-FY EPS reported -$5.31 revenue$314,000

Cash, cash equivalents and short-term investments ~$645.7M as of Jan 31, 2024 (preliminary), extending runway into H2 2026.
Net loss for FY2023 was $237.7M vs $129.9M in 2022; R&D expenses rose to $159.8M.
VRDN-001 Phase 3 THRIVE topline data expected mid-2024; THRIVE-2 at year-end 2024.
VRDN-003 subcutaneous pivotal program expected to start mid-2024 pending regulatory alignment.
FcRn inhibitor VRDN-006 IND submission anticipated by year-end 2024; VRDN-008 NHP data H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Viridian Therapeutics, Inc.\DE reported preliminary financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: preliminary results

Exact text from the filing

Viridian Therapeutics, Inc. (the “Company”) issued a press release reporting financial results for the fourth quarter and year ended December 31, 2023.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-24-047916

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.